The Inflammatory and Hemostatic Response in Sepsis and Meningococcemia

Boeddha, Navin P.; Bycroft, Thomas; Nadel, Simon; Hazelzet, Jan A.

doi:10.1016/j.ccc.2019.12.005

Cited by 10 publications

(4 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A previous study understood that severe infections trigger an inflammatory host response, leading to activation of the endothelial dysfunction and hemostatic response. 42 The data presented here further support the integration of inflammatory cytokine storms with hemostatic abnormality. In critically ill patients, the levels of interleukin and TNF surpassed those of PCT, affirming the predictive value of interleukin and TNF in forecasting worse prognosis.…”

Section: Discussionsupporting

confidence: 72%

Sepsis-induced Coagulopathy: The Different Prognosis in Severe Pneumonia and Bacteremia Infection Patients

Liufu,

Chen,

Wan

et al. 2023

Clin Appl Thromb Hemost

View full text Add to dashboard Cite

Sepsis-induced coagulopathy (SIC) is a critical condition in sepsis patients, with varying outcomes depending on the type of infection. This study aims to analyze the prognosis of different infections in SIC cohort. A retrospective cohort study was conducted on 525 patients diagnosed with SIC in the intensive care unit from December 2013 to December 2022. These patients were divided into four groups: a non-pneumonia or bacteremia group, a severe pneumonia group, a bacteremia group, and a severe pneumonia concomitant with bacteremia group. The 28-day mortality was 18% (49/271) in the other infections group, 31% (33/106) in the lung infections group, 23% (29/126) in the blood infections group and 36% (8/36) in the lung and blood co-infections group, respectively. Pearson correlation analysis showed that procalcitonin (PCT) correlated strongly with all detected hemostatic markers ( p < 0.001). The 28-day mortality rate in Lung infections group was significantly higher ( p = 0.019), while Blood infections group had a higher incidence of disseminated intravascular coagulation ( p = 0.011). By multivariable model analyses, longer duration of ventilation ( p = 0.039) and severe pneumonia ( p = 0.040) are risk factors associated with mortality. Different infections, including Lung and Blood infections, indicated different conditions in vivo. Longer duration of ventilation is associated with mortality, while Lung infections indicated higher 28-day mortality rate.

show abstract

Section: Discussionsupporting

confidence: 72%

Sepsis-induced Coagulopathy: The Different Prognosis in Severe Pneumonia and Bacteremia Infection Patients

Liufu,

Chen,

Wan

et al. 2023

Clin Appl Thromb Hemost

View full text Add to dashboard Cite

show abstract

“…Sepsis is caused by an imbalanced host immune response, with excessive inflammation and an inadequate resolution of the inflammation. 34,35 SPMs have therefore become an area of interest in the management of sepsis. 36 While antiinflammatory therapies could potentially harm septic patients, improving the resolution phase of inflammation appears to allow an adequate immune response and improve the clearance of the bacterial pathogen.…”

Section: Sepsismentioning

confidence: 99%

“…Unfortunately, the clinical management of sepsis is still less than optimal. Sepsis is caused by an imbalanced host immune response, with excessive inflammation and an inadequate resolution of the inflammation 34,35 . SPMs have therefore become an area of interest in the management of sepsis 36 .…”

Section: Spms In Bacterial Infectionsmentioning

confidence: 99%

Specialized proresolving mediators in infection and lung injury

Sandhaus

Swick

2020

BioFactors

View full text Add to dashboard Cite

Specialized proresolving mediators (SPMs) are endogenous lipid metabolites of long-chain polyunsaturated fatty acids that are involved in promoting the resolution of inflammation. Many disease conditions characterized by excessive inflammation have impaired or altered SPM biosynthesis, which may lead to chronic, unresolved inflammation. Exogenous administration of SPMs in infectious conditions has been shown to be effective at improving infection clearance and survival in preclinical models. SPMs have also shown tremendous promise in the context of inflammatory lung conditions, such as acute respiratory distress syndrome and chronic obstructive pulmonary disease, mostly in preclinical settings. To date, SPMs have not been studied in the context of the novel Coronavirus, severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2), however their preclinical efficacy in combatting infections and improving acute respiratory distress suggest they may be a valuable resource in the fight against Coronavirus disease-19 (COVID-19). Overall, while the research on SPMs is still evolving, they may offer a novel therapeutic option for inflammatory conditions.

show abstract

“…Septic shock has a high death rate due to tissue damage, organ circulation abnormalities, and cell metabolism issues caused by an intense inflammatory response. After the pathogen is recognized by immune cells in the early stages of septic shock, immune cells such as neutrophils and mononuclear macrophages are activated (4,5), and proinflammatory cytokines such as TNF-α and IL-6 are generated and released (6,7). In the late stage of infection, injured cells and immune cells bind to Toll-like receptor 4 (TLR 4) and activate signal transduction pathways such as NF-κB (8), which further release inflammatory factors such as TNF-α and IL-6 and aggravate tissue damage.…”

Section: Introductionmentioning

confidence: 99%